EC research programme positive for devices industry:
This article was originally published in Clinica
Eucomed, the European medical device industry association, has welcomed enthusiastically the European Commission's proposal for its next research programme, confident that it promises "fertile conditions" in which the medical devices industry will innovate and thrive. "We are pleased to see that a particular emphasis has been placed on the development and validation of new therapies, diagnostic tools and technologies," director general Maurice Wagner, has commented on the 7th Framework Programme for Research 2007-2013. The industry association has expressed its approval at seeing nanotechnology and emerging technologies as receiving particular attention, using the opportunity to highlight the potential that nanotechnology has in terms of future cancer treatment.
You may also be interested in...
With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.